IDEAS home Printed from https://ideas.repec.org/a/spr/drugsa/v42y2019i2d10.1007_s40264-018-0770-z.html
   My bibliography  Save this article

Safety of Novel Targeted Therapies in Oncology

Author

Listed:
  • Rashmi R. Shah
  • Giuseppe Curigliano

    (European Institute of Oncology IRCCS
    University of Milan)

Abstract

No abstract is available for this item.

Suggested Citation

  • Rashmi R. Shah & Giuseppe Curigliano, 2019. "Safety of Novel Targeted Therapies in Oncology," Drug Safety, Springer, vol. 42(2), pages 157-158, February.
    • Handle: RePEc:spr:drugsa:v:42:y:2019:i:2:d:10.1007_s40264-018-0770-z
    DOI: 10.1007/s40264-018-0770-z
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s40264-018-0770-z
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1007/s40264-018-0770-z?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Rashmi R. Shah & Devron R. Shah, 2019. "Safety and Tolerability of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in Oncology," Drug Safety, Springer, vol. 42(2), pages 181-198, February.
    2. Giuseppe Curigliano & Rashmi R. Shah, 2019. "Safety and Tolerability of Phosphatidylinositol-3-Kinase (PI3K) Inhibitors in Oncology," Drug Safety, Springer, vol. 42(2), pages 247-262, February.
    3. Rashmi R. Shah, 2019. "Safety and Tolerability of Histone Deacetylase (HDAC) Inhibitors in Oncology," Drug Safety, Springer, vol. 42(2), pages 235-245, February.
    4. Iosune Baraibar & Ignacio Melero & Mariano Ponz-Sarvise & Eduardo Castanon, 2019. "Safety and Tolerability of Immune Checkpoint Inhibitors (PD-1 and PD-L1) in Cancer," Drug Safety, Springer, vol. 42(2), pages 281-294, February.
    5. Letizia Procaccio & Vera Damuzzo & Francesca Sarra & Alberto Russi & Federica Todino & Vincenzo Dadduzio & Francesca Bergamo & Alessandra Anna Prete & Sara Lonardi & Hans Prenen & Angelo Claudio Paloz, 2019. "Safety and Tolerability of Anti-Angiogenic Protein Kinase Inhibitors and Vascular-Disrupting Agents in Cancer: Focus on Gastrointestinal Malignancies," Drug Safety, Springer, vol. 42(2), pages 159-179, February.
    6. Alberto Puccini & Nagore I. Marín-Ramos & Francesca Bergamo & Marta Schirripa & Sara Lonardi & Heinz-Josef Lenz & Fotios Loupakis & Francesca Battaglin, 2019. "Safety and Tolerability of c-MET Inhibitors in Cancer," Drug Safety, Springer, vol. 42(2), pages 211-233, February.
    7. Danilo Rocco & Ciro Battiloro & Luigi Della Gravara & Cesare Gridelli, 2019. "Safety and Tolerability of Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer," Drug Safety, Springer, vol. 42(2), pages 199-209, February.
    8. Benita Wolf & Stefan Zimmermann & Caroline Arber & Melita Irving & Lionel Trueb & George Coukos, 2019. "Safety and Tolerability of Adoptive Cell Therapy in Cancer," Drug Safety, Springer, vol. 42(2), pages 315-334, February.
    9. Richard L. Carpenter & Haimanti Ray, 2019. "Safety and Tolerability of Sonic Hedgehog Pathway Inhibitors in Cancer," Drug Safety, Springer, vol. 42(2), pages 263-279, February.
    10. Anna Wolska-Washer & Tadeusz Robak, 2019. "Safety and Tolerability of Antibody-Drug Conjugates in Cancer," Drug Safety, Springer, vol. 42(2), pages 295-314, February.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Sebastian Schmidt & Malte D. Luecken & Dietrich Trümbach & Sina Hembach & Kristina M. Niedermeier & Nicole Wenck & Klaus Pflügler & Constantin Stautner & Anika Böttcher & Heiko Lickert & Ciro Ramirez-, 2022. "Primary cilia and SHH signaling impairments in human and mouse models of Parkinson’s disease," Nature Communications, Nature, vol. 13(1), pages 1-25, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:drugsa:v:42:y:2019:i:2:d:10.1007_s40264-018-0770-z. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com/economics/journal/40264 .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.